Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 8, Issue 10, Pages 1643-1650Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.8.10.1643
Keywords
chemoembolization; drug-eluting embolization agent; HCC; hepatocellular carcinoma; locoregional percutaneous treatment; particulate embolization material; TACE; transcatheter arterial chemoembolization
Categories
Ask authors/readers for more resources
The advantage of chemoembolization of the liver as an antineoplastic treatment for hepatocellular carcinoma is that it achieves high intratumoral concentrations of the chemotherapeutic agent locally that cannot be reached with systemic chemotherapy in nontoxic doses. However, chemotherapeutic release and local concentrations cannot be standardized by this technique. Drug-eluting beads have predictable pharmacokinetics and can achieve higher doses of the chemotherapeutic and prolonged contact time with cancer cells. The DC Bead (TM) is a drug-eluting bead that has proven favorable kinetics and clinical characteristics. This review describes the features of the DC Bead loaded with doxorubicin for the treatment of hepatocellular carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available